Project Grant R01CA309413
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $512K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Netherlands
Similar Awards
- The National Cancer Institute awarded $457,683 to Beckman Research Institute of The City of Hope on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of ERBB signaling in ibrutinib-resistant mantle cell lymphoma (MCL). The research elucidates mechanisms by which MCL tumors evade BTK inhibition through ERBB-mediated survival pathways. The recipient will analyze gene expression patterns in ibrutinib-resistant MCL patient samples, develop isogenic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Feinstein Institutes for Medical Research a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This research initiative addresses chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the United States, by investigating the cellular and molecular mechanisms underlying communication between cancer cells and...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded Yale University $677,621 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a blood test for early detection of non-Hodgkin's lymphoma in people with HIV. The research measures altered methylation patterns of tumor-derived cell-free DNA fragments in blood as biomarkers of lymphomagenesis, specifically evaluating hypermethylation of Epstein-Barr virus DNA and gene promoters in infected B cell genomes that arise...
- The National Institutes of Health National Cancer Institute awarded The Medical University of South Carolina $211,778 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to optimize a single-cell multi-omics analysis platform for circulating and therapeutic immune cells. The funded work develops and standardizes analyte profiles detectable in CD4, CD8, CD14, CD19, CD16, and CD56 immune cells isolated from cancer-associated peripheral blood mononuclear...
- The National Cancer Institute awarded the University of Chicago $547,740 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the molecular mechanisms by which the MLL1 histone modification complex and the long noncoding RNA HOTTIP interact in acute myeloid leukemia pathogenesis. The research examines whether non-specific RNA binding to the WDR5 subunit of the MLL1 complex inhibits the complex's histone methyltransferase activity and whether the RBBP5...
- The National Cancer Institute awarded Weill Medical College of Cornell University $425,741 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the molecular mechanisms of MGA loss-of-function in Richter transformation, an aggressive lymphoma arising in chronic lymphocytic leukemia patients. The research elucidates how MGA gene inactivation, present in approximately 29 percent of Richter transformation cases, drives tumor cell fitness, B-cell clonal...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $137,631 on July 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to fund research on mutant splicing factor-derived protein isoforms in clonal hematopoietic disorders and antigen presentation. The award funds basic research investigating how somatic mutations in RNA splicing factor genes (U2AF1, SF3B1, and SRSF2) drive myelodysplastic syndromes and related clonal hematopoietic conditions. The...
- The National Cancer Institute awarded $467,261 to Hackensack University Medical Center on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate myeloid phagocyte activation by commensal-activated complement C5AR1 signaling in colorectal cancer. The research examines how tumor-associated microbes—specifically Candida albicans and Fusobacterium nucleatum, two microorganisms enriched in colorectal cancer—amplify C5AR1 signaling to shape the tumor...
- The National Cancer Institute awarded Mayo Clinic $558,016 on May 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate accelerated biological aging and immunosenescence as drivers of racial disparities in monoclonal gammopathy of undetermined significance (MGUS). The funded research examines why multiple myeloma and its precursor condition MGUS occur at disproportionately high rates and younger average ages in individuals of African ancestry. The project tests the...